365 related articles for article (PubMed ID: 19485898)
21. Succinate reverses in-vitro platelet inhibition by acetylsalicylic acid and P2Y receptor antagonists.
Spath B; Hansen A; Bokemeyer C; Langer F
Platelets; 2012; 23(1):60-8. PubMed ID: 21736422
[TBL] [Abstract][Full Text] [Related]
22. P2Y
Hensch NR; Karim ZA; Pineda J; Mercado N; Alshbool FZ; Khasawneh FT
Biochem Biophys Res Commun; 2017 Nov; 493(2):1069-1074. PubMed ID: 28928091
[TBL] [Abstract][Full Text] [Related]
23. Blocking the EP3 receptor for PGE2 with DG-041 decreases thrombosis without impairing haemostatic competence.
Tilly P; Charles AL; Ludwig S; Slimani F; Gross S; Meilhac O; Geny B; Stefansson K; Gurney ME; Fabre JE
Cardiovasc Res; 2014 Mar; 101(3):482-91. PubMed ID: 24323317
[TBL] [Abstract][Full Text] [Related]
24. P2Y₁₂ and EP3 antagonists promote the inhibitory effects of natural modulators of platelet aggregation that act via cAMP.
Iyú D; Glenn JR; White AE; Fox SC; Dovlatova N; Heptinstall S
Platelets; 2011; 22(7):504-15. PubMed ID: 21591981
[TBL] [Abstract][Full Text] [Related]
25. Blocking receptors on the inside: pepducin-based intervention of PAR signaling and thrombosis.
Kuliopulos A; Covic L
Life Sci; 2003 Dec; 74(2-3):255-62. PubMed ID: 14607253
[TBL] [Abstract][Full Text] [Related]
26. The progress in the research of antiplatelet agents (1995-2017).
Benimana O; Zhao L; Kong Y; Li Z; Xie Z
Future Med Chem; 2017 Jun; 9(10):1087-1110. PubMed ID: 28632424
[TBL] [Abstract][Full Text] [Related]
27. Antiplatelet Agents Affecting GPCR Signaling Implicated in Tumor Metastasis.
Rovati G; Contursi A; Bruno A; Tacconelli S; Ballerini P; Patrignani P
Cells; 2022 Feb; 11(4):. PubMed ID: 35203374
[TBL] [Abstract][Full Text] [Related]
28. Antiplatelet therapy in patients with diabetes mellitus.
Grove EL; Gregersen S
Curr Vasc Pharmacol; 2012 Jul; 10(4):494-505. PubMed ID: 22272895
[TBL] [Abstract][Full Text] [Related]
29. Pharmacotherapeutic Targeting of G Protein-Coupled Receptors in Oncology: Examples of Approved Therapies and Emerging Concepts.
Lappano R; Maggiolini M
Drugs; 2017 Jun; 77(9):951-965. PubMed ID: 28401445
[TBL] [Abstract][Full Text] [Related]
30. Allosteric inhibition of g-protein coupled receptor oligomerization: strategies and challenges for drug development.
Hurevich M; Talhami A; Shalev DE; Gilon C
Curr Top Med Chem; 2014; 14(15):1842-63. PubMed ID: 25175995
[TBL] [Abstract][Full Text] [Related]
31. G Protein-Coupled Receptors in Asthma Therapy: Pharmacology and Drug Action.
Wendell SG; Fan H; Zhang C
Pharmacol Rev; 2020 Jan; 72(1):1-49. PubMed ID: 31767622
[TBL] [Abstract][Full Text] [Related]
32. Regulators of platelet cAMP levels: clinical and therapeutic implications.
Noé L; Peeters K; Izzi B; Van Geet C; Freson K
Curr Med Chem; 2010; 17(26):2897-905. PubMed ID: 20858171
[TBL] [Abstract][Full Text] [Related]
33. Established and In-trial GPCR Families in Clinical Trials: A Review for Target Selection.
Saikia S; Bordoloi M; Sarmah R
Curr Drug Targets; 2019; 20(5):522-539. PubMed ID: 30394207
[TBL] [Abstract][Full Text] [Related]
34. Current and future antiplatelet therapies: emphasis on preserving haemostasis.
McFadyen JD; Schaff M; Peter K
Nat Rev Cardiol; 2018 Mar; 15(3):181-191. PubMed ID: 29297508
[TBL] [Abstract][Full Text] [Related]
35. Approval of the first protease-activated receptor antagonist: Rationale, development, significance, and considerations of a novel anti-platelet agent.
French SL; Arthur JF; Tran HA; Hamilton JR
Blood Rev; 2015 May; 29(3):179-89. PubMed ID: 25467961
[TBL] [Abstract][Full Text] [Related]
36. The 7 TM G-protein-coupled receptor target family.
Jacoby E; Bouhelal R; Gerspacher M; Seuwen K
ChemMedChem; 2006 Aug; 1(8):761-82. PubMed ID: 16902930
[TBL] [Abstract][Full Text] [Related]
37. Quantitative and systems pharmacology 2. In silico polypharmacology of G protein-coupled receptor ligands via network-based approaches.
Wu Z; Lu W; Yu W; Wang T; Li W; Liu G; Zhang H; Pang X; Huang J; Liu M; Cheng F; Tang Y
Pharmacol Res; 2018 Mar; 129():400-413. PubMed ID: 29133212
[TBL] [Abstract][Full Text] [Related]
38. Timosaponin AIII induces antiplatelet and antithrombotic activity via Gq-mediated signaling by the thromboxane A2 receptor.
Cong Y; Wang L; Peng R; Zhao Y; Bai F; Yang C; Liu X; Wang D; Ma B; Cong Y
Sci Rep; 2016 Dec; 6():38757. PubMed ID: 27934923
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of Ebola and Marburg Virus Entry by G Protein-Coupled Receptor Antagonists.
Cheng H; Lear-Rooney CM; Johansen L; Varhegyi E; Chen ZW; Olinger GG; Rong L
J Virol; 2015 Oct; 89(19):9932-8. PubMed ID: 26202243
[TBL] [Abstract][Full Text] [Related]
40. Mechanisms of platelet activation: need for new strategies to protect against platelet-mediated atherothrombosis.
Jennings LK
Thromb Haemost; 2009 Aug; 102(2):248-57. PubMed ID: 19652875
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
